Bristol-Myers Squibb gets rated a hold, as I see future value in its clinical portfolio and pipeline, particularly ...
In an amicus brief, several advocacy groups warned that letting the lawsuit proceed past a motion to dismiss could open the ...
Bristol-Myers Squibb’s $2.6B pension risk transfer lawsuit is ‘frivolous,’ say industry groups
The ERISA Industry Committee, along with two other industry groups, is seeking the dismissal of the drugmaker’s PRT lawsuit ...
Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...
Deep-pocketed investors have adopted a bearish approach towards Bristol-Myers Squibb (NYSE:BMY), and it's something market players shouldn't ignore. Our tracking of public options records at ...
The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. Sotyktu, which became the first TYK2 inhibitor to reach the market after its 2022 ...
Whales with a lot of money to spend have taken a noticeably bearish stance on Bristol-Myers Squibb. Looking at options history for Bristol-Myers Squibb BMY we detected 26 trades. If we consider ...
Bristol Myers Squibb believes Alzheimer's treatment is the largest potential market for its newly approved schizophrenia drug, Cobenfy, which it expects to eventually generate billions of dollars ...
Financial giants have made a conspicuous bullish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb BMY revealed 10 unusual trades. Delving into the details ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback